Recognizing that school-based interventions to improve rates of obesity in children have generally been originated by university-based teams and have had a mixed record of success, these investigators studied the results of a multicomponent School Nutrition Policy Initiative (SNPI) developed by a community-based organization, The Food Trust, for the Philadelphia school district. The objective was to prevent overweight [body mass index (BMI) for age from the 85.0th to 94.9th percentile] and obesity (BMI for age 995th percentile) in 4th, 5th, and 6th grade children over a 2-year period. An advance year was spent in preparatory work, during which committees using Center for Disease Control and Prevention guidelines on healthy eating worked with the district's Food Services Division to make food changes in the intervention schools and plan the six components of the SNPI: school selfassessment, staff training, nutrition education, nutrition policy, social marketing, and family outreach.
Prevalence of obesity, both at baseline and after 2 years, did not change significantly or differ between the two groups, ranging from 24% to 28%. Remission rates for overweight and obesity also did not differ for the two groups. With respect to dietary intake, physical activity, and body image, no differences were found between the groups. Small but significant reductions in hours of total inactivity and total weekday television watching were reported by children in the intervention schools compared to controls.
COMMENTARY
No one ever said it would be easy. With rare exceptions, most children have immune systems that will produce antibodies in response to a vaccine and protect them against a particular infection. No such quick fix exists for excessive weight gain, nor is one likely to be found soon. Does that mean that more closely targeted interventions should be replaced by the kind of very elaborate comprehensive approach used in this study? Considering the rather modest results, with some success in prevention of overweight but none for obesity, the authors suggest that obesity prevention and control most likely does require targeted or clinical intervention, but broader public health strategies may be justified for the control of overweight. They also wisely suggest that interventions should begin before the 4th grade.
Although the broad outlines of this policy intervention were the same in all the study schools, much individual variation and considerable ingenuity were displayed throughout its implementation. For instance, some schools limited the use of food as reward, punishment, or for fundraising; some promoted active recess; some integrated nutrition topics in the classroom such as using food labels to practice fractions or nutrition topics for writing assignments; some actively discouraged sending sweets to teachers as holiday gifts; and one established a weekly breakfast club with female athletes from a local university. The sheer number of such items might compromise a rigorous evaluation, and even pose a challenge for a scaled up initiative, but they surely must have contributed to an increased awareness of healthy living that has too often been missing in the schoolroom and public square.
In the long run, regardless of what specific approaches ultimately prove to be most effective against the problem of overweight and obesity, healthier lifestyles for the next generation will be an almost certain, if unintended, consequence of the broad range of interventions currently underway.
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SUMMARY
Given the individual and societal economic pressures to reduce prescription drug expenditures, the use of generic equivalents for brand-name drugs has increased. Because little information exists about the pattern of generic and brand-name drug use in children, this study examined data from the 2002 Medical Expenditure Panel Survey conducted by the Agency for Healthcare Research and Quality in order to compare the type of drug use by medical condition, therapeutic class, child demographics, insurance status, and health status. Information was obtained from household report, medical providers, and pharmacies. The latter provided total charges and payment sources for the prescriptions.
Of the 24,465 prescriptions reported for 5,696 children (aged 0 to 17 years), 40.6% were generic. High percentages of generics were prescribed for otitis media and asthma; antibiotics, analgesics, and bronchodilators were predominantly generic (∼70%). Mean expenditure for generic drugs in this sample was $20.92; for brand names, it was $71.65. The largest differences in mean expenditures between drug types were for bronchodilators ($25.21 vs. $98.33 ) and dermatologic agents ($12.73 vs. $54.53) . Multiple logistic regression analysis revealed significantly higher odds ratios (ORs) for generic dispensing for girls than boys, Asian than white, and uninsured than privately insured children. ORs for black, Hispanic, and publicly insured children, and low income families were not significantly different from the reference variable.
COMMENTARY
These authors hypothesized that socially and economically disadvantaged children might be more likely to receive generic drugs than brand-name ones, and they suggest that brand-name medication use is "perhaps potentially superior therapeutically". The arguments for brand-name superiority are that newer and presumably more efficacious drugs may not have generic equivalents and that there have been therapeutic failures with certain generics because generics may receive less than optimal testing for bioequivalence and trials for efficacy. If generics are indeed inferior and they are more likely to be dispensed to certain categories of children (girls, Asians, uninsured), then we can claim another example of disparities in health care. But, regardless of the calculated odds ratios, for every population group in this study, at least half the prescriptions were for brand-name drugs; likewise, no one would argue that all generics are inferior. In the absence of clinical outcome data, one could plausibly claim that when children are prescribed a generic drug, in many situations, they may be just as likely get a positive therapeutic effect as not. The conclusion would be that although this paper does show some differences in dispensing patterns, a difference is not necessarily a disparity with all the negative connotations that surround the latter term.
Meanwhile, the shocking price differentials between brand name and generic drugs are bound to trump every other prescribing consideration, and not just for disadvantaged populations. The American consumer may indeed believe that a more expensive product is a better one, but figures such as these strain the bounds of such a belief.
